Pine Pharmaceuticals is pleased to announce the expansion of our 503B outsourcing facility located at 355 Riverwalk Parkway in Tonawanda, NY. Originally built in 2018, our facility will triple in size to meet our tremendous growth and provide an unprecedented level of service to our customers.
The 50,000-square-foot expansion includes a state-of-the-art facility designed from the ground up to comply with the US Food and Drug Administration’s Current Good Manufacturing Practice (cGMP). The new space will enable additional manufacturing, quality control, and warehousing to meet the extraordinary demand for sterile compounded pharmaceuticals. Construction is set to begin next month.
In partnership with New York State, the expansion effort will create 40 additional jobs at Pine Pharmaceuticals over the next five years and seeks to stimulate the local Buffalo economy during the COVID-19 crisis.
“This expansion marks the start of an exciting time for our company, our community, and our industry,” said Alfonse Muto, Owner of Pine Pharmaceuticals. “With New York State’s support, we will be able to dramatically increase the production of essential drugs that people around the country rely on every day and enrich our local economy for years to come.”
You can read more about Pine Pharmaceuticals’ expansion, including comments from Governor Cuomo, here: http://on.ny.gov/3sY8lqH.
Pine Pharmaceuticals is an FDA-registered, cGMP-compliant, 503B outsourcing facility. All products are available non-patient-specific with no prescriptions required. For more information, please visit www.PinePharmaceuticals.com or email sales@pinepharmaceuticals.com to learn more about our products and services.